Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013284 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL1013285 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL7870676 | 0.98 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL9000001 | 0.98 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL4623579 | 0.83 | CA12 (0.41) | TAAR1SLC6A2SLC7A5CA2 | |
| SCHEMBL15951403 | 0.83 | TAAR1 (0.59) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL8855721 | 0.83 | TSHR (0.39) | TAAR1SLC6A2SLC7A5CA2 | |
| SCHEMBL2269394 | 0.81 | CYP3A4 (0.42) | TAAR1SLC7A5CA2 | |
| SCHEMBL242931 | 0.81 | CYP3A4 (0.42) | TAAR1SLC7A5CA2 | |
| SCHEMBL6670843 | 0.81 | HRH3 (0.48) | TAAR1SLC6A2ABATCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167109-A1 | Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation | UNIV EMORY (US) | 2023-06-01 | — | — | US | claimed |
| WO-2021217143-A1 | AMINOPIPERIDINE AMIDES, DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 MODULATION | EMORY UNIVERSITY (US) | 2021-10-28 | — | — | WO | claimed |
| EP-3725797-B1 | STABILIZED LIQUID ENZYME COMPOSITIONS | NOVOZYMES AS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | AJINOMOTO CO., INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023106897-A1 | NOVEL PEPTIDE DERIVATIVE DERIVED FROM ADIPONECTIN AND USE THEREOF | 서울대학교병원 | 2023-06-15 | — | — | WO | disclosed |
| US-20230167109-A1 | Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation | UNIV EMORY (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4169381-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | AJINOMOTO CO., INC. (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-107090014-B | Stabilized liquid enzyme compositions | 诺维信公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-0585412-A1 | INCREASING BLOOD-BRAIN BARRIER PERMEABILITY WITH PERMEABILIZER PEPTIDES | ALKERMES, INC. (US) | 1994-03-09 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| WO-1992018529-A1 | INCREASING BLOOD-BRAIN BARRIER PERMEABILITY WITH PERMEABILIZER PEPTIDES | ALKERMES, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0199085-B1 | JOMOL, ITS DERIVATIVES, PROCESS FOR THE PREPARATION OF THESE SUBSTANCES, THEIR USE AND THEIR PRODUCTION | Ehrenfeld, Udo, Dr. (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-5116614-A | JOMOL DERIVATIVES AS AGENTS FOR THE USE IN MALIGNANT TUMORS AND LOWERED IMMUNE DEFENSES | EHRENFELD UDO (DE) | 1992-05-26 | — | — | US | disclosed |
| US-5053216-A | Diagnosis,therapy of malignant tumors | EHRENFELD UDO (DE) | 1991-10-01 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0199085-A2 | Jomol, its derivatives, process for the preparation of these substances, their use and their production | Ehrenfeld, Udo, Dr. (DE) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167109-A1 | Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation | CXCR4, CXCR2, CXCL12 | TAAR1 375/4885SLC6A2 691/4885SLC7A5 2223/4885 |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | DAO, ALAD, BCAT1 | TAAR1 181/4885SLC6A2 313/4885SLC7A5 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.